Based only on the facts in our directory. The right pick still depends on the job you need done.
Lower starting price
Not comparable
Not comparable: Artera does not list a price
Free plan
Tie
Neither has one
Higher rating
Artera
4.4 against 4.1
Same job?
Yes
Both are Healthcare AI tools
Side by side
Compared on
Artera
Paige
Our rating
4.4Better
4.1
Starts at
Not listed
Not listed
Free plan
No
No
Category
Healthcare AI
Healthcare AI
Plans
See pricing
See pricing
Key features
Multimodal AI trained on digitized biopsy images paired with clinical data
FDA De Novo authorization for the ArteraAI Prostate Test
FDA clearance for ArteraAI Breast digital pathology risk stratification
Results delivered in as little as two days after sample submission
Inclusion in National Comprehensive Cancer Network (NCCN) treatment guidelines
Paige Alba AI co-pilot for digital pathology tissue-slide analysis
Cancer diagnosis, tissue subtyping, and molecular biomarker discovery support
Founded in 2017 by researchers from Memorial Sloan Kettering Cancer Center
Acquired by Tempus in August 2025, continuing under its own brand
Enterprise deployment with dedicated support for hospital and lab pathology teams
Pros
Regulatory clearance (FDA De Novo, NCCN guideline inclusion) beyond most AI health startups
Published clinical evidence showing improved outcome prediction versus existing risk models
Adopted by a meaningful share of US prostate cancer clinicians already
Research pedigree from Memorial Sloan Kettering lends real clinical credibility
Tempus backing adds financial resources and precision-medicine data integration
Deep oncology pathology specialization outperforms general-purpose medical imaging AI
Cons
Not a self-serve software product; access runs through labs, clinicians, and insurance billing
Pricing is not public and varies by payer and region
Limited to prostate and breast cancer currently, not a general oncology platform
Enterprise-only pricing requires a sales conversation before evaluation
Now part of a larger company, a real change from its independent-startup years
Narrow pathology focus means it's not a fit for non-oncology diagnostic workflows
Company
Artera, founded 2021
Paige, founded 2017
Prices come from each vendor's pricing page, last checked 20260802. Check the vendor before you buy.
FAQ
Questions people ask
Is Artera better than Paige?
In our reviews Artera scores 4.4 and Paige scores 4.1. The better pick depends on the job. Artera: FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions. Paige: Digital pathology AI co-pilot from Memorial Sloan Kettering researchers, acquired by Tempus in 2025.
Artera
Paige
